Search
Imunon Inc
IMNNAdd to Watchlist
1.780USD
-0.020-1.11%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
7.48MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.11%
5 Days
0.00%
1 Month
-18.35%
6 Months
-53.28%
Year to Date
-53.28%
1 Year
-82.94%
Key Figures
1.790Open
1.905High
93.78KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.74%Turnover Ratio
1.800Prev. Close
1.725Low
109.48KTurnover
LossP/E Static
0.86P/B
0.00%Div Yield TTM
-196.78%ROA
41.21752wk High
1.42Volume Ratio
-18.62MNet Profit
3.42MShares
-3.9958EPS TTM
1.97Beta
-768.25%ROE
2.08052wk Low
10.00%Amplitude
100.00%Gross Margin
7.48MMarket Cap
-3.87Reward/Risk
4.21%Risk Rate
TradingKey Stock Score of Imunon Inc
Currency: USD Updated: 2026-06-30Key Insights
Imunon Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 156 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Imunon Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Imunon Inc Highlights
StrengthsRisks
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Undervalued
The company’s latest PE is -0.45, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 431.10K shares, increasing 9.85% quarter-over-quarter.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
17.000
Target Price
+844.44%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Imunon Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Imunon Inc Info
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Ticker SymbolIMNN
CompanyImunon Inc
CEOLindborg (Stacy R)
Websitehttps://imunon.com/
Related Instruments
-2.50%
-1.79%
-1.22%
-0.57%
-0.73%
-0.56%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
52112.500
-83.800 (-0.16%)
30077.100
-147.500 (-0.49%)
7460.700
-21.700 (-0.29%)
15295.000
-300.000 (-1.92%)
70431.000
-425.000 (-0.60%)
6302.000
-25.000 (-0.40%)
69.308
-0.613 (-0.88%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
3968.620
-38.660 (-0.96%)
FAQs
What is the current price of Imunon Inc (IMNN)?
The current price of Imunon Inc (IMNN) is 1.78.
What is the symbol of Imunon Inc?
The ticker symbol of Imunon Inc is IMNN.
What is the 52-week high of Imunon Inc?
The 52-week high of Imunon Inc is 41.22.
What is the 52-week low of Imunon Inc?
The 52-week low of Imunon Inc is 2.08.
What is the market capitalization of Imunon Inc?
The market capitalization of Imunon Inc is 6.09M.
Is Imunon Inc (IMNN) currently rated as Buy, Hold, or Sell?
According to analysts, Imunon Inc (IMNN) has an overall rating of Buy, with a price target of 17.00.
What is the Earnings Per Share (EPS TTM) of Imunon Inc (IMNN)?
The Earnings Per Share (EPS TTM) of Imunon Inc (IMNN) is -6.83.
